RayKnowChina Research Map
Shortlist

Hebei Medical University

河北医科大学

ShijiazhuangUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.08%Leads under 1 in 100 of China's research papers on NPC

Led 2 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.06%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025
ThemesRecurrent / metastatic diseaseImaging & AI

Hospitals counted here

  1. Second Hospital of Hebei Medical University Counted in the group total2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
4.6%Leads about 1 in 22 of China's research papers on ESCC ▲ from 3.5%

Led 134 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
11
Research papers it led
134
Trials it led
18
Share of China's trials
3.2%
Share of the world's papers
3.1%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 332025
ThemesRadiotherapyNeoadjuvant & combined treatmentImmunotherapy

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Fourth Hospital of Hebei Medical University123
  2. Second Hospital of Hebei Medical University5
  3. North China Petroleum Bureau General Hospital1
  4. First Hospital, Hebei Medical University1
  5. Hebei Medical University Third Affiliated Hospital1
  6. First Hospital of Hebei Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Apatinib Combined with Paclitaxel and Cisplatin Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.2022Cancer biotherapy & radiopharmaceuticalsRCT
  2. The prognostic value of tumor deposits in esophageal squamous cell carcinoma: A propensity score matching study.2026European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  3. Outcomes and predictive factors in post-surgical resection of sT4a esophageal cancer.2025World journal of surgical oncologyFree full text
  4. Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab versus neoadjuvant chemotherapy plus tislelizumab for locally advanced esophageal squamous cell cancer: a real-world retrospective study.2025Frontiers in immunologyFree full text
  5. Comparative study of neoadjuvant chemoradiotherapy, chemotherapy, and chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma.2025BMC cancerFree full text
Trials on ClinicalTrials.gov6
  1. Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCCNot yet recruitingNCT07697040Lead sponsorPhase 1Start 2026-07
  2. Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07823270Lead sponsorPhase 2Start 2026-10
  3. Paclitaxel Polymeric Micelles and Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07799077Lead sponsorPhase 2Start 2026-09
  4. Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)Not yet recruitingNCT06903871Lead sponsorPhase 2Start 2025-04
  5. Clinical Study of Adbelimumab in the Adjuvant Treatment of Esophageal Squamous Cell Carcinoma.RecruitingNCT07266480Lead sponsorPhase 2Start 2025-09
  6. A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)Not yet recruitingNCT07112833Lead sponsorPhase 2Start 2025-08

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
0.5%Leads under 1 in 100 of China's research papers on HCC

Led 74 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
1
Research papers it led
74
Trials it led
5
Share of China's trials
0.3%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 332025
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection

Hospitals counted here

  1. Fourth Hospital of Hebei Medical University20
  2. Third Hospital of Hebei Medical University18
  3. Second Hospital of Hebei Medical University Counted in the group total8
  4. First Hospital of Hebei Medical University8
  5. Hebei Medical University Third Hospital Counted in the group total4
  6. Third Affiliated Hospital of Hebei Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Transcatheter arterial chemoembolization with or without bevacizumab in hepatocellular carcinoma with portal vein invasion: a randomized trial.2025Cancer imaging : the official publication of the International Cancer Imaging SocietyRCTFree full text
  2. A study on the safety and effectiveness of transcatheter arterial chemoembolization and bevacizumab arterial infusion combined as a comprehensive treatment for hepatocellular carcinoma.2025Annals of hepatologyRCT
  3. Bicarbonate ringer's solution could improve the intraoperative acid-base equilibrium and reduce hepatocellular enzyme levels after deceased donor liver transplantation: a randomized controlled study.2023BMC anesthesiologyRCTFree full text
  4. Effect of camrelizumab plus transarterial chemoembolization on massive hepatocellular carcinoma.2022Clinics and research in hepatology and gastroenterologyRCT
  5. LEAST as a novel prediction model of hepatocellular carcinoma development in patients with chronic hepatitis B: a multi-center study.2025BMC medicineFree full text
Trials on ClinicalTrials.gov6
  1. Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular CarcinomaRecruitingNCT07179900Lead sponsorPhase 2Start 2025-03
  2. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Study sitePhase 1Start 2025-11
  3. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  4. Evaluation of AKR1B10 as a New Marker for Interventional Therapy of Hepatocellular CarcinomaStatus unknownNCT06272656Lead sponsorStart 2024-04
  5. Dietary Intervention and Gut Microbiota in Hepatocellular Carcinoma (HCC)CompletedNCT07143955Lead sponsorN/AStart 2022-05
  6. TACE With Immune Agents for Angiogenesis in Hepatocellular CarcinomaCompletedNCT07053202Lead sponsorN/AStart 2021-10

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
1.5%Leads about 1 in 68 of China's research papers on Stomach cancer

Led 143 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
8
Research papers it led
143
Trials it led
24
Share of China's trials
1.6%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 112025
ThemesPeritoneal spread & advanced diseaseImaging & AIImmunotherapy & targeted drugs

Hospitals counted here

  1. Fourth Hospital of Hebei Medical University104
  2. Second Hospital of Hebei Medical University23
  3. First Hospital of Hebei Medical University4
  4. Third Hospital of Hebei Medical University Counted in the group total3
  5. Hebei Medical University Third Hospital Counted in the group total2
  6. Cangzhou Central Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Use of machine learning-based integration to develop an immune-related signature for improving prognosis in patients with gastric cancer.2023Scientific reportsRCTFree full text
  2. Assessment of Carbon Nanoparticle Suspension Lymphography-Guided Distal Gastrectomy for Gastric Cancer.2022JAMA network openFree full text
  3. Safety and feasibility of robot-assisted remote radical gastrectomy for gastric cancer based on 5G communication technology (FUTURE-04): a prospective, single-arm clinical trial.2026Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  4. Diagnostic value of SSTR2A, ATRX, and clusterin immunohistochemical expression in high-grade gastroenteropancreatic neuroendocrine neoplasms.2026Annals of diagnostic pathology
  5. Efficacy of traditional Chinese medicine in the conservative management of complete small intestinal obstruction post-gastric cancer surgery: A case report.2025Explore (New York, N.Y.)
Trials on ClinicalTrials.gov6
  1. Silent Evaluation of DeepTRG for Assessing Tumor Response After Preoperative Treatment in Stomach and Gastroesophageal Junction CancerRecruitingNCT07849608Lead sponsorStart 2026-09
  2. DeepComp for Prediction of Gastric Cancer Postoperative Complications (DeepComp-Prospective)RecruitingNCT07401173Lead sponsorStart 2026-03
  3. Multimodal Deep Learning for Lymph Node Metastasis Prediction and Physician Performance Assessment in T1 Gastric CancerRecruitingNCT07124754Lead sponsorStart 2025-01
  4. Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)RecruitingNCT07289997Lead sponsorPhase 2Start 2025-09
  5. A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10Not yet recruitingNCT07304258Lead sponsorPhase 2Start 2025-12
  6. AI-Based Prediction of Lymph Node Metastasis in Gastric Cancer Using Preoperative Multimodal DataEnrolling by invitationNCT06957678Lead sponsorStart 2025-01

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
0.6%Leads under 1 in 100 of China's research papers on Osteosarcoma

Led 14 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
14
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 2220242025: 222025

Hospitals counted here

  1. Third Hospital of Hebei Medical University7
  2. Fourth Hospital of Hebei Medical University6
  3. Hebei Medical University Third Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
1.7%Leads about 1 in 58 of China's research papers on Gastrointestinal stromal tumour ▲ from 0.8%

Led 9 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 1120222023: 3320232024: 1120242025: 002025

Hospitals counted here

  1. Fourth Hospital of Hebei Medical University7
  2. First Hospital of Hebei Medical University1
  3. Second Hospital of Hebei Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
1.0%Leads under 1 in 100 of China's research papers on Neuroblastoma

Led 11 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
11
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 1120242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Second Hospital of Hebei Medical University6
  2. Third Hospital of Hebei Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
0.7%Leads under 1 in 100 of China's research papers on Myeloma

Led 12 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
0
Research papers it led
12
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 4420242025: 002025
ThemesDiagnosis, MRD & riskDrug combinationsStem cell transplant

Hospitals counted here

  1. Fourth Hospital of Hebei Medical University4
  2. Second Hospital of Hebei Medical University3
  3. Third Hospital of Hebei Medical University2
  4. Hebei Medical University Third Hospital Counted in the group total1
  5. First Hospital of Hebei Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Effects of Consolidation Therapy With Autologous Hematopoietic Stem Cell Transplantation After BCMA-CAR T-Cell Therapy on the Survival of Patients With Relapsed or Refractory Multiple Myeloma.2024Transplantation and cellular therapy
  2. Brain Nocardiosis Mimicking Intracerebral Invasion on 68 Ga-Pentixafor PET/CT in a Patient With Multiple Myeloma.2024Clinical nuclear medicine
  3. Unusual extramedullary presentation in newly diagnosed multiple myeloma: Synchronous infiltration of the maxillary sinus, thyroid, breast and bilateral ovaries.2024Asian journal of surgery
  4. Small intestinal angiodysplasia and hemorrhage associated with acquired von Willebrand syndrome type 2A secondary to multiple myeloma: Reversal after treatment with IRD regimen (a case report and a brief review of the li2024Thrombosis research
  5. Multiple myeloma following bone metastasis of renal cell carcinoma: a case report.2023Frontiers in endocrinologyFree full text
Trials on ClinicalTrials.gov6
  1. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  2. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  3. 68Ga-BCMA PET/CT in Multiple MyelomaRecruitingNCT07319897Study sitePhase 2/Phase 3Start 2025-12
  4. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingNCT04973605Study sitePhase 1/Phase 2Start 2021-09
  5. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsRecruitingNCT05020236Study sitePhase 3Start 2021-10
  6. A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaStatus unknownNCT05236621Study sitePhase 3Start 2021-01

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
0.0%Leads none of China's research papers on Aplastic anaemia

Led 0 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
1
Share of China's trials
1.0%
Share of the world's papers
0.0%
Trials on ClinicalTrials.gov1
  1. Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Aplastic AnemiaStatus unknownNCT03055078Lead sponsorPhase 1Start 2017-01

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
1.0%Leads about 1 in 100 of China's research papers on HLH

Led 4 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 1120242025: 112025
ThemesChildrenEBV & infection triggersGenetics & inherited forms

Hospitals counted here

  1. Fourth Hospital of Hebei Medical University2
  2. Hebei Children's Hospital, Hebei Medical University1
  3. Second Hospital of Hebei Medical University1
  4. First Hospital of HeBei Medical University1
  5. Hebei Children's Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
3.5%Leads about 1 in 28 of China's research papers on NMOSD New since 2021

Led 17 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
0
Research papers it led
17
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 3320242025: 112025
ThemesAcute attack treatmentAntibodies & diagnosisRelapse prevention

Hospitals counted here

  1. Second Hospital of Hebei Medical University16
  2. Third Hospital of Hebei Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
1.6%Leads about 1 in 62 of China's research papers on Myasthenia gravis ▲ from 0.4%

Led 8 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 222025
ThemesThymus & thymectomyAntibodies & diagnosisPregnancy, children, older adults

Hospitals counted here

  1. People's Hospital, Hebei Medical University3
  2. Fourth Hospital of Hebei Medical University2
  3. Hebei Medical University Third Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
0.8%Leads under 1 in 100 of China's research papers on Moyamoya New since 2021

Led 3 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 112025
ThemesStroke & bleeding outcomesRevascularisation surgeryImaging & blood flow

Hospitals counted here

  1. Second Hospital of Hebei Medical University2
  2. First Hospital of Hebei Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Biliary atresia

胆道闭锁
0.9%Leads under 1 in 100 of China's research papers on Biliary atresia New since 2021

Led 2 of 214 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025
ThemesKasai operationLiver transplant

Hospitals counted here

  1. Hebei Medical University Third Hospital Counted in the group total1
  2. Second Hospital of Hebei Medical University Counted in the group total1
  3. Third Hospital of Hebei Medical University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
0.4%Leads under 1 in 100 of China's research papers on Idiopathic pulmonary fibrosis New since 2021

Led 4 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 112025

Hospitals counted here

  1. Second Hospital of Hebei Medical University3
  2. Affiliated Xing Tai People Hospital of Hebei Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
3.1%Leads about 1 in 32 of China's research papers on Amyotrophic lateral sclerosis ▼ from 5.7%

Led 24 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
24
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 442025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Second Hospital of Hebei Medical University19

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Fabry disease

法布雷病
2.7%Leads about 1 in 36 of China's research papers on Fabry disease New since 2021

Led 2 of 73 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.3%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Second Hospital of Hebei Medical University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Duchenne muscular dystrophy

杜氏肌营养不良
1.9%Leads about 1 in 53 of China's research papers on Duchenne muscular dystrophy New since 2021

Led 4 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.8%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 222025

Hospitals counted here

  1. Second Hospital of Hebei Medical University4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
0.4%Leads under 1 in 100 of China's research papers on IgA nephropathy

Led 3 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 002025

Hospitals counted here

  1. Second Hospital of Hebei Medical University2
  2. Fourth Hospital of Hebei Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
0.7%Leads under 1 in 100 of China's research papers on Primary biliary cholangitis ▼ from 2.0%

Led 2 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

Hospitals counted here

  1. Second Hospital of Hebei Medical University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov